lipodystrophy is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-04-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
The peptide is supplied as a lyophilized powder in single-use vials and is normally kept refrigerated between two and eight degrees Celsius, protected from light. Once dissolved, the solution is handled carefully because peptide bonds and the acyl modification can degrade under warm or alkaline conditions. Vials are inspected for cracks, and the powder is checked for color and uniformity before handling. Temperature excursions during shipping are a frequent reason for quality questions.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from truncated or oxidized forms. Mass spectrometry confirms the expected molecular weight, and peptide mapping after enzymatic digestion verifies the amino acid sequence. Water content is measured because residual moisture affects stability, and tests for aggregates or particulates are standard for injectable peptides. Circular dichroism can indicate whether the molecule has adopted an unexpected secondary structure in solution.
Research supply is often accompanied by a certificate of analysis listing chromatographic purity, mass confirmation, and storage conditions. Laboratories compare that document with an independent test when material is intended for bench work, since certificates describe a batch rather than an individual vial. Published studies usually state the source and purity of the peptide because small differences in purity can shift measured activity. Full analytical validation is rarely reported, which leaves batch-to-batch comparability an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
稳定性研究通常考察温度、光照、湿度和 pH 对肽链的影响。冻干粉在低温避光条件下较为稳定，复溶后则需控制保存时间并避免反复冻融。肽类可能发生氧化、脱酰胺、水解和聚集，这些变化会改变色谱纯度。强制降解实验用于识别主要降解途径并验证分析方法的专属性。
质量控制项目一般包括外观、身份、纯度、含量、有关物质、水分和微生物限度。身份确认可通过肽图谱、氨基酸分析和质谱完成，纯度则用面积归一化法计算。研究级材料与药品级材料的要求不同，前者常缺少完整药典验证。不同批次间杂质谱是否影响活性，仍是一个需要具体数据回答的问题。
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Stability testing examines how the molecule changes under controlled stress. Thermal stress, light exposure, and extremes of pH are applied separately so that each degradation route can be attributed to a specific cause. The main observed changes are oxidation, deamidation, and aggregation into dimers or higher-order species. Accelerated studies at elevated temperature are used to estimate behavior over longer periods, though such extrapolation carries uncertainty. For a lyophilized powder, residual moisture and the choice of bulking agent strongly influence how quickly these changes appear.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
==== Heat-sensing pits ==== Aside from their eyes, rattlesnakes are able to detect thermal radiation emitted by warm-blooded organisms in their environment. Functioning optically like a pinhole camera eye, thermal radiation in the form of infrared light passes through the opening of the pit and strikes the pit membrane located in the back wall, warming this part of the organ. Due to the high density of heat-sensitive receptors innervating this membrane, the rattlesnake can detect temperature changes of 0.003 °C or less in its immediate surroundings. Infrared cues from these receptors are transmitted to the brain by the trigeminal nerve, where they are used to create thermal maps of the snake's surroundings. Due to the small sizes of the pit openings, typically these thermal images are low in resolution and contrast. Nevertheless, rattlesnakes superimpose visual images created from information from the eyes with these thermal images from the pit organs to more accurately visualize their surroundings in low levels of light. Research conducted recently on the molecular mechanism of this ability suggests the temperature sensitivity of these pit organs is closely linked to the activity of transient receptor potential ankyrin 1, a temperature-sensitive ion channel saturated in the pit membrane.
== Origin == Missense mutations may be inherited or arise spontaneously, termed de novo mutations. Well studied diseases arising from inherited missense mutations include sickle cell anemia, cystic fibrosis, and early-onset Alzheimer's and Parkinson's disease. De novo mutations that increase or decrease the activity of synapses have been implicated in the development of neurological and developmental disorders, such a Autism Spectrum Disorder and intellectual delay.
== Law enforcement and defence == Founded in 1981, the Ciskei Defence Force consisted of two battalions and an air wing. Ciskei Police Ciskei Police – Law Enforcement Division Ciskei Prisons Service Ciskei Traffic Force
Sources: en.wikipedia.org
=== For El Niño === 1789-1790 influenza epidemic 1982–83 El Niño event 1997 Pacific hurricane season 1997–98 El Niño event 2014–2016 El Niño event 2015 Pacific hurricane season 2023–2024 El Niño event 2026–2027 El Niño event
In 1898, Marie and Pierre Curie discovered a strongly radioactive substance in pitchblende and determined that it was a new element; it was one of the first radioactive elements discovered. Having identified it as such, they named the element polonium after Marie's home country, Poland. Willy Marckwald discovered a similar radioactive activity in 1902 and named it radio-tellurium as it was chemically extracted with its homolog tellurium, and at roughly the same time, Ernest Rutherford identified the same activity in his analysis of the uranium decay chain and named it radium F (originally radium E). By 1905, Rutherford concluded that all these observations were due to the same substance, 210Po. Further discoveries and the concept of isotopes, first proposed in 1913 by Frederick Soddy, firmly placed 210Po as the penultimate step in the uranium series. In 1943, 210Po was studied as a possible neutron initiator in nuclear weapons, as part of the Dayton Project. In subsequent decades, concerns for the safety of workers handling 210Po led to extensive studies on its health effects. In the 1950s, scientists of the United States Atomic Energy Commission at Mound Laboratories, Ohio explored the possibility of using 210Po in radioisotope thermoelectric generators (RTGs) as a heat source to power satellites. A 2.5-watt atomic battery using 210Po was developed by 1958. However, the isotope plutonium-238 was chosen instead, as it has a longer half-life of 87.7 years. Polonium-210 was used to kill Russian dissident and ex-FSB officer Alexander V.
=== Polyendocrine metabolic ovarian syndrome === In those with polyendocrine metabolic ovarian syndrome (PMOS), tentative evidence shows that metformin use increases the rate of live births. This includes those who have not been able to get pregnant with clomiphene. Metformin does not appear to change the risk of miscarriage. A number of other benefits have also been found both during pregnancy and in nonpregnant people with PMOS. In an updated Cochrane review on metformin versus placebo/no treatment before or during IVF/ICSI in women with PMOS, no conclusive evidence of improved live birth rates was found. In long GnRH-agonist protocols there was uncertainty in the evidence of improved live birth rates but there could be increases in clinical pregnancy rate. In short GnRH-antagonist protocols metformin may reduce live birth rates with uncertainty on its effect on clinical pregnancy rate. Metformin may result in a reduction of OHSS but could come with a greater frequency of side effects. There was uncertainty as to metformin's impact on miscarriage. The evidence does not support general use during pregnancy for improving maternal and infant outcomes in obese women. The United Kingdom's National Institute for Health and Clinical Excellence recommended in 2004 that people with PMOS and a body mass index above 25 be given metformin for anovulation and infertility when other therapies fail to produce results.
Sources: en.wikipedia.org
A variety of geologic and environmental settings have been proposed for an origin of life. These theories are often in competition with one another as there are many views of prebiotic compound availability, geophysical setting, and early life characteristics. The first organism on Earth likely differed from LUCA. Between the first appearance of life and where all modern phylogenies began branching, an unknown amount of time passed, with unknown gene transfers, extinctions, and adaptation to environmental niches. Modern phylogenies provide more genetic evidence about LUCA than about its precursors.
Dupuytren disease is generally considered painless, but can be painful if nerve tissue is involved, although this is not usually discussed in the literature. The most common finger to be affected is the ring finger; the thumb and index finger are much less often affected. The disease begins in the palm and moves towards the fingers, with the metacarpophalangeal (MCP) joints affected before the proximal interphalangeal (PIP) joints. The MCP joints at the base of the finger responds much better to treatment and are usually able to fully extend after treatment. Due to anatomic differences in the ligaments and extensor tendons at the PIP joints, they may have some residual flexion. Proper patient education is necessary to set realistic treatment expectation. In Dupuytren's contracture, the palmar fascia within the hand becomes abnormally thick, which can cause the fingers to curl and can impair finger function. The main function of the palmar fascia is to increase grip strength; thus, over time, Dupuytren's contracture decreases a person's ability to hold objects and use the hand in many different activities. Dupuytren's contracture can also be experienced as embarrassing in social situations and can affect quality of life. People may report pain, aching, and itching with the contractions. Normally, the palmar fascia consists of collagen type I, but in Dupuytren patients, the collagen changes to collagen type III, which is significantly thicker than collagen type I.
Navy expeditions continued to be plagued by scurvy even while fresh (not jerked or tinned) meat was well known as a practical antiscorbutic among civilian whalers and explorers in the Arctic. In the latter half of the 19th century, there was greater recognition of the value of eating fresh meat as a means of avoiding or treating scurvy, but the lack of available game to hunt at high latitudes in winter meant it was not always a viable remedy. Criticism also focused on the fact that some of the men most affected by scurvy on Naval polar expeditions had been heavy drinkers, with suggestions that this predisposed them to the condition. Even cooking fresh meat did not destroy its antiscorbutic properties, especially as many cooking methods failed to bring all the meat to high temperature. The confusion is attributed to several factors:
Resistance to lidocaine and bupivacaine is not uncommon, and mepivacaine tends to work better in people with EDS. Special recommendations for anesthesia are given for people with EDS. Detailed recommendations for anesthesia and perioperative care of people with EDS should be used to improve safety. Surgery in people with EDS requires careful tissue handling and a longer immobilization afterward.
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
Lyophilized material is typically kept refrigerated and away from light in the sealed vial provided. Dissolved material is generally used within a limited period rather than stored long term.